CYT 100
Alternative Names: CYT-100Latest Information Update: 20 Nov 2022
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer; Solid tumours
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 07 Nov 2022 Pharmacodynamics data from preclinical trial in Solid tumours released by Cytovia Therapeutics
- 27 Apr 2022 Cytovia Therapeutics plans phase I/II trials in Liver cancer (Monotherapy, Combination therapy)
- 19 Apr 2022 Discontinued for Acute myeloid leukaemia in USA (Parenteral) (Cytovia Therapeutics pipeline, April 2022)